An internationally renowned group of scientists, researchers and clinicians will work with Aviceda’s in-house team to spearhead development of the next generation of glyco-immune therapeutics

It’s the final nail in the coffin for Catabasis Pharmaceuticals’ Duchenne muscular dystrophy (DMD) hopeful as edasalonexent has once again failed to deliver.

Foundation Medicine has nabbed a U.S. green light as the only companion diagnostic for Bayer’s Vitrakvi (larotrectinib).

Neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) cause damage to nerve fibers that can’t be reversed. Now, scientists at Ohio State University and the University of Michigan have discovered an immune cell they believe could be harnessed to partially reverse this damage and slow MS, ALS and other neurodegenerative disorders.

On the heels of a $278 million IPO, Forma Therapeutics is inching toward its first FDA filing. Its lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with acute myeloid leukemia (AML) that had returned despite undergoing treatment or who did not respond to treatment in the first place.

Japanese pharma Eisai is boosting its 2019 pact with Australian medtech firm Cogstate and its cognitive function test.

Machine learning drug development company insitro has bought up Haystack Sciences, adding DNA-encoded libraries (DELs) to its R&D arsenal.

This summer, Pfizer teamed up with other Big Pharmas on a $1 billion fund to bolster struggling antibiotics makers. Now, the company is adding a new antibiotic candidate to its pipeline through its acquisition of Arixa. If approved, the prospect could be the first new drug of its kind in more than 35 years.

Alnylam has shared data from a phase 3 trial of its near-approval kidney disease drug lumasiran in children as young as three months. The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.

PARP inhibitors like Lynparza from Merck and AstraZeneca have been effective in some patients with ovarian and breast cancers, but many develop resistance to the drugs, and some people don’t respond at all. KSQ Therapeutics hopes to provide hope for those patients with a first-in-class drug that may be able to boost Lynparza’s effectiveness when used in combination with it—and the company has rolled out promising animal data to back up that strategy.